

Special Issue

Cancer Vaccines and Combination Immunotherapies

Message from the Guest Editors

Dear colleagues, This Special Issue, titled “Cancer Immunotherapy: Vaccines and Combination Immunotherapies” will focus on fundamental research on cancer vaccines and combination immunotherapies. Special attention will be given to the topic of targeted cancer vaccines and combination immunotherapies aimed at modifying the tumor microenvironment, as well as the challenges associated with the development of these novel therapeutic approaches. We invite you to share original research articles as well as up to date reviews. Research areas may include (but are not limited to) the following: neoantigen vaccines, cancer therapeutic vaccines, combination immunotherapy, DNA vaccines, dendritic cell-based vaccines, cell-based vaccines, nucleic-acid-based vaccines, neoadjuvant therapy, immune checkpoint therapy, nanoparticle immune therapy, anti-CTLA-4 therapy, anti-PDX therapy, and adoptive cell therapy. We look forward to receiving your contributions.

Guest Editors

Dr. Jessica Chacon

Texas Tech University Health Sciences Center, El Paso, TX, USA

Dr. Richard Wu

Wexner Medical Center, Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (30 April 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/141870

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).